drugset / Trial / NCT02267213
Efficacy and Safety Study of TLC388 to Advanced Hepatocellular Carcinoma
NaSingle-groupOpen-labelTreatment
Summary
The purpose of this study is to evaluate the safety and efficacy of TLC388 (Lipotecan) as a second line treatment in subjects with advanced Hepatocellular Carcinoma.
Timeline
- Start
- 2014-04-10
- Primary completion
- 2015-07-09
- Completion
- 2015-07-09
Outcome
Outcome not reported
Stopped: “Current study design couldn't support futher development on this indication”
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | TLC388 | Small molecule | 40 mg/m2 | Intravenous |